<DOC>
	<DOCNO>NCT00980174</DOCNO>
	<brief_summary>The purpose study assess effective safe denosumab population male low bone mass risk fracture . The primary clinical hypothesis men low bone mineral density , mean percent change lumbar spine bone mineral density 12 month subject receive denosumab great subject receive placebo . Denosumab fully human monoclonal antibody high affinity Receptor Activator Nuclear Factor ( RANK ) Ligand bind neutralize activity human RANK Ligand similar action endogenous osteoprotegerin .</brief_summary>
	<brief_title>Study Compare Efficacy Safety DenosumAb Versus Placebo Males With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Bone Mineral Density ( BMD ) value ( g/cm2 ) assess local site either lumbar spine OR femoral neck occur within range specify protocol OR For subject history major osteoporotic fracture ( clinical vertebral , hip , humerus distal radius fracture ) occur 6 month prior screen , BMD value ( g/cm2 ) assess local site , either lumbar spine OR femoral neck occur within range specify protocol . At least 2 lumbar vertebra , least 1 hip least one forearm must evaluable Dual X ray Absorptiometry ( DXA ) . Ambulatory males 30 85 year age inclusive start screening . Provide appropriate write informed consent study specific procedure . BMD value ( g/cm2 ) specify protocol subject without history major osteoporotic fracture , base particular scanner use . Any disorder compromise ability subject give write informed consent and/or comply study procedure . Any severe 1 moderate vertebral fracture screen spinal x ray Any vertebral fracture diagnose within 6 month prior screen Any clinical fracture within last 6 month prior screen For male partner childbearing potential : Subject refuse use 2 highly effective method contraception duration study 10 month last dose study medication . For male partner pregnant : Subject refuse use condom duration study 10 month last dose study medication . Previous participation clinical trial denosumab administration commercial denosumab . Currently enrol yet complete least 1 month since end investigational device drug trial ( ) , subject receive investigational agent ( ) . Vitamin D deficiency [ 25 ( OH ) vitamin D level &lt; 20 ng/mL ( &lt; 49.9 nmol/L ) ] . Vitamin D replenishment permit subject may rescreened ; see Section 7 . Hyper hypothyroidism ; however , stable subject , investigator 's opinion , thyroid hormone replacement therapy allow . Hyper hypoparathyroidism . Intact parathyroid hormone ( iPTH ) value outside reference range determine central laboratory Elevated transaminase . Serum aspartate aminotransferase ; serum glutamateoxaloacetic transaminase &gt; 2.5 x upper limit normal . Serum alanine aminotransferase ; serum glutamate pyruvate transaminase &gt; 2.5 x upper limit normal ( determined central laboratory ) . Significantly impaired renal function determine derived glomerular filtration rate ( use Modification Diet Renal Disease formula ) less equal 30 mL/min/1.73 m2 calculate central laboratory . Hypo hypercalcemia base central laboratory reference range albuminadjusted serum calcium . Known test positive human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen cirrhosis liver . Malignancy ( except fully resect cutaneous basal cell squamous cell carcinoma ) within last 5 year . Any metabolic bone disease , eg osteomalacia , osteogenesis imperfecta , rheumatoid arthritis , Paget 's disease , Cushing 's disease , hyperprolactinemia may interfere interpretation finding OR evidence malabsorption syndrome might interfere absorption vitamin D. Received solid organ bone marrow transplant chronic immunosuppression reason . Any laboratory abnormality , opinion investigator Amgen , prevent subject complete study interfere interpretation study result . Administration intravenous bisphosphonate , fluoride ( except dental treatment ) strontium ranelate . Oral bisphosphonate treatment : great equal 3 month cumulatively past 2 year , OR great equal 1 month past year , OR Any use 3month period prior randomization Administration follow treatment 3 month prior screen : Anabolic steroid testosterone Glucocorticosteroids ( great equal 5 mg prednisone equivalent per day 10 day total cumulative dose great equal 50 mg ) Calcitonin Calcitriol vitamin D derivatives [ vitamin D contain supplement multivitamin allow ] Other bone active drug include anticonvulsives ( except benzodiazepine ) heparin Chronic systemic ketoconazole , adrenocorticotrophic hormone ( ACTH ) , cinacalcet , aluminum , lithium , protease inhibitor , methotrexate , gonadotropinreleasing hormone agonist . Androgen deprivation therapy Known sensitivity mammalian cell derive drug product . Known intolerance calcium vitamin D supplement . Height , weight girth may preclude accurate DXA measurement . Bilateral hip replacement Any physical psychiatric disorder , opinion investigator Amgen , prevent subject complete study interfere interpretation study result . Evidence alcohol substanceabuse within last 12 month investigator believe would interfere understand completion study .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>men</keyword>
	<keyword>male</keyword>
	<keyword>denosumab</keyword>
	<keyword>BMD</keyword>
	<keyword>lumbar spine</keyword>
	<keyword>ADAMO</keyword>
	<keyword>The ADAMO Trial</keyword>
	<keyword>male osteoporosis</keyword>
	<keyword>osteoporosis men</keyword>
	<keyword>male low bone mineral density</keyword>
</DOC>